Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 08 2023
16 08 2023
Historique:
received:
18
11
2022
accepted:
03
08
2023
medline:
18
8
2023
pubmed:
17
8
2023
entrez:
16
8
2023
Statut:
epublish
Résumé
Drug-induced liver injury induced by already approved substances is a major threat to human patients, potentially resulting in drug withdrawal and substantial loss of financial resources in the pharmaceutical industry. Trovafloxacin, a broad-spectrum fluoroquinolone, was found to have unexpected side effects of severe hepatotoxicity, which was not detected by preclinical testing. To address the limitations of current drug testing strategies mainly involving 2D cell cultures and animal testing, a three-dimensional microphysiological model of the human liver containing expandable human liver sinusoidal endothelial cells, monocyte-derived macrophages and differentiated HepaRG cells was utilized to investigate the toxicity of trovafloxacin and compared it to the structurally-related non-toxic drug levofloxacin. In the model, trovafloxacin elicited vascular and hepatocellular toxicity associated with pro-inflammatory cytokine release already at clinically relevant concentrations, whereas levofloxacin did not provoke tissue injury. Similar to in vivo, cytokine secretion was dependent on a multicellular immune response, highlighting the potential of the complex microphysiological liver model for reliably detecting drug-related cytotoxicity in preclinical testing. Moreover, hepatic glutathione depletion and mitochondrial ROS formation were elucidated as intrinsic toxicity mechanisms contributing to trovafloxacin toxicity.
Identifiants
pubmed: 37587168
doi: 10.1038/s41598-023-40004-z
pii: 10.1038/s41598-023-40004-z
pmc: PMC10432496
doi:
Substances chimiques
trovafloxacin
9F388J00UK
Levofloxacin
6GNT3Y5LMF
Fluoroquinolones
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13338Informations de copyright
© 2023. Springer Nature Limited.
Références
Stevens, J. L. & Baker, T. K. The future of drug safety testing: Expanding the view and narrowing the focus. Drug Discov. Today 14, 162–167. https://doi.org/10.1016/j.drudis.2008.11.009 (2009).
doi: 10.1016/j.drudis.2008.11.009
pubmed: 19100337
Watkins, P. B. Drug safety sciences and the bottleneck in drug development. Clin. Pharmacol. Ther. 89, 788–790. https://doi.org/10.1038/clpt.2011.63 (2011).
doi: 10.1038/clpt.2011.63
pubmed: 21593756
Wysowski, D. K. & Swartz, L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: The importance of reporting suspected reactions. Arch. Intern. Med. 165, 1363–1369. https://doi.org/10.1001/archinte.165.12.1363 (2005).
doi: 10.1001/archinte.165.12.1363
pubmed: 15983284
Sgro, C. et al. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 36, 451–455. https://doi.org/10.1053/jhep.2002.34857 (2002).
doi: 10.1053/jhep.2002.34857
pubmed: 12143055
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B. & Olafsson, S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144, 1419-1425.e1413. https://doi.org/10.1053/j.gastro.2013.02.006 (2013).
doi: 10.1053/j.gastro.2013.02.006
pubmed: 23419359
Shin, J. et al. Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data. Pharmacoepidemiol. Drug Saf. 22, 190–198. https://doi.org/10.1002/pds.3388 (2013).
doi: 10.1002/pds.3388
pubmed: 23258383
Vega, M. et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: Preliminary findings from gastroenterologist-based surveillance in the population of the State of Delaware. Drug Saf. 40, 783–787. https://doi.org/10.1007/s40264-017-0547-9 (2017).
doi: 10.1007/s40264-017-0547-9
pubmed: 28555362
pmcid: 5699929
Shen, T. et al. Incidence and etiology of drug-induced liver injury in Mainland China. Gastroenterology 156, 2230-2241.e2211. https://doi.org/10.1053/j.gastro.2019.02.002 (2019).
doi: 10.1053/j.gastro.2019.02.002
pubmed: 30742832
Schiødt, F. V. et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl. Surg. 5, 29–34. https://doi.org/10.1002/lt.500050102 (1999).
doi: 10.1002/lt.500050102
pubmed: 9873089
Ostapowicz, G. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137, 947–954. https://doi.org/10.7326/0003-4819-137-12-200212170-00007 (2002).
doi: 10.7326/0003-4819-137-12-200212170-00007
pubmed: 12484709
Russo, M. W., Galanko, J. A., Shrestha, R., Fried, M. W. & Watkins, P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 10, 1018–1023. https://doi.org/10.1002/lt.20204 (2004).
doi: 10.1002/lt.20204
pubmed: 15390328
Bernal, W., Auzinger, G., Dhawan, A. & Wendon, J. Acute liver failure. Lancet 376, 190–201. https://doi.org/10.1016/S0140-6736(10)60274-7 (2010).
doi: 10.1016/S0140-6736(10)60274-7
pubmed: 20638564
Chalasani, N. P. et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am. J. Gastroenterol. 109, 950–966. https://doi.org/10.1038/ajg.2014.131 (2014).
doi: 10.1038/ajg.2014.131
pubmed: 24935270
Chalasani, N. & Björnsson, E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 138, 2246–2259. https://doi.org/10.1053/j.gastro.2010.04.001 (2010).
doi: 10.1053/j.gastro.2010.04.001
pubmed: 20394749
Fontana, R. J. et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 147, 96-108.e104. https://doi.org/10.1053/j.gastro.2014.03.045 (2014).
doi: 10.1053/j.gastro.2014.03.045
pubmed: 24681128
Chalasani, N. et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 148, 1340-1352.e1347. https://doi.org/10.1053/j.gastro.2015.03.006 (2015).
doi: 10.1053/j.gastro.2015.03.006
pubmed: 25754159
Andrade, R. J. et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the spanish registry over a 10-year period. Gastroenterology 129, 512–521. https://doi.org/10.1053/j.gastro.2005.05.006 (2005).
doi: 10.1053/j.gastro.2005.05.006
pubmed: 16083708
Ball, P., Mandell, L., Niki, Y. & Tillotson, G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 21, 407–421. https://doi.org/10.2165/00002018-199921050-00005 (1999).
doi: 10.2165/00002018-199921050-00005
pubmed: 10554054
Shaw, P. J., Hopfensperger, M. J., Ganey, P. E. & Roth, R. A. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol. Sci. 100, 259–266. https://doi.org/10.1093/toxsci/kfm218 (2007).
doi: 10.1093/toxsci/kfm218
pubmed: 17709330
Sarro, D. A. & Sarro, D. G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr. Med. Chem. 8, 371–384. https://doi.org/10.2174/0929867013373435 (2001).
doi: 10.2174/0929867013373435
pubmed: 11172695
Van Bambeke, F. & Tulkens, P. M. Safety profile of the respiratory fluoroquinolone moxifloxacin. Drug Saf. 32, 359–378. https://doi.org/10.2165/00002018-200932050-00001 (2009).
doi: 10.2165/00002018-200932050-00001
pubmed: 19419232
Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56–67. https://doi.org/10.1006/rtph.2000.1399 (2000).
doi: 10.1006/rtph.2000.1399
pubmed: 11029269
Butler, L. D. et al. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective. Regul. Toxicol. Pharmacol. 87, S1–S15. https://doi.org/10.1016/j.yrtph.2017.05.009 (2017).
doi: 10.1016/j.yrtph.2017.05.009
pubmed: 28483710
Nguyen, D. G. et al. Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PloS One 11, e0158674. https://doi.org/10.1371/journal.pone.0158674 (2016).
doi: 10.1371/journal.pone.0158674
pubmed: 27387377
pmcid: 4936711
Li, F., Cao, L., Parikh, S. & Zuo, R. Three-dimensional spheroids with primary human liver cells and differential roles of Kupffer cells in drug-induced liver injury. J. Pharm. Sci. 109, 1912–1923. https://doi.org/10.1016/j.xphs.2020.02.021 (2020).
doi: 10.1016/j.xphs.2020.02.021
pubmed: 32145211
Vernetti, L. A. et al. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp. Biol. Med. (Maywood) 241, 101–114. https://doi.org/10.1177/1535370215592121 (2016).
doi: 10.1177/1535370215592121
pubmed: 26202373
Ewart, L. et al. Performance assessment and economic analysis of a human liver-chip for predictive toxicology. Commun. Med. 2, 154. https://doi.org/10.1038/s43856-022-00209-1 (2022).
doi: 10.1038/s43856-022-00209-1
pubmed: 36473994
pmcid: 9727064
Rennert, K. et al. A microfluidically perfused three dimensional human liver model. Biomaterials 71, 119–131. https://doi.org/10.1016/j.biomaterials.2015.08.043 (2015).
doi: 10.1016/j.biomaterials.2015.08.043
pubmed: 26322723
Kaden, T. et al. Generation & characterization of expandable human liver sinusoidal endothelial cells and their application to assess hepatotoxicity in an advanced in vitro liver model. Toxicology 483, 153374. https://doi.org/10.1016/j.tox.2022.153374 (2023).
doi: 10.1016/j.tox.2022.153374
pubmed: 36396002
Spiess, M. The asialoglycoprotein receptor: A model for endocytic transport receptors. Biochemistry 29, 10009–10018. https://doi.org/10.1021/bi00495a001 (1990).
doi: 10.1021/bi00495a001
pubmed: 2125488
Shi, B., Abrams, M. & Sepp-Lorenzino, L. Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J. Histochem. Cytochem. 61, 901–909. https://doi.org/10.1369/0022155413503662 (2013).
doi: 10.1369/0022155413503662
pubmed: 23979840
pmcid: 3840742
Cerec, V. et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45, 957–967. https://doi.org/10.1002/hep.21536 (2007).
doi: 10.1002/hep.21536
pubmed: 17393521
Hayes, J. D., Flanagan, J. U. & Jowsey, I. R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 45, 51–88. https://doi.org/10.1146/annurev.pharmtox.45.120403.095857 (2004).
doi: 10.1146/annurev.pharmtox.45.120403.095857
Smedsrød, B. Clearance function of scavenger endothelial cells. Comp. Hepatol. 3(Suppl 1), S22–S22. https://doi.org/10.1186/1476-5926-2-S1-S22 (2004).
doi: 10.1186/1476-5926-2-S1-S22
pubmed: 14960174
pmcid: 2409441
Taylor, P. R. et al. Macrophage receptors and immune recognition. Annu. Rev. Immunol. 23, 901–944. https://doi.org/10.1146/annurev.immunol.23.021704.115816 (2004).
doi: 10.1146/annurev.immunol.23.021704.115816
Shaw, P. J., Ganey, P. E. & Roth, R. A. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol. Sci. 118, 7–18. https://doi.org/10.1093/toxsci/kfq168 (2010).
doi: 10.1093/toxsci/kfq168
pubmed: 20538741
pmcid: 2955207
Hsiao, C.-J.J., Younis, H. & Boelsterli, U. A. Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction. Chem. Biol. Interact. 188, 204–213. https://doi.org/10.1016/j.cbi.2010.07.017 (2010).
doi: 10.1016/j.cbi.2010.07.017
pubmed: 20655887
Ito, Y., Bethea, N. W., Abril, E. R. & McCuskey, R. S. Early hepatic microvascular injury in response to acetaminophen toxicity. Microcirculation 10, 391–400. https://doi.org/10.1038/sj.mn.7800204 (2003).
doi: 10.1038/sj.mn.7800204
pubmed: 14557822
Kostadinova, R. et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 268, 1–16. https://doi.org/10.1016/j.taap.2013.01.012 (2013).
doi: 10.1016/j.taap.2013.01.012
pubmed: 23352505
Waring, J. F. et al. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J. Pharmacol. Exp. Ther. 316, 1080. https://doi.org/10.1124/jpet.105.096347 (2006).
doi: 10.1124/jpet.105.096347
pubmed: 16299187
Shaw, P. J. et al. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol. Sci. 107, 270–280. https://doi.org/10.1093/toxsci/kfn205 (2009).
doi: 10.1093/toxsci/kfn205
pubmed: 18930950
Shaw, P. J. et al. Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol. Sci. 111, 288–301. https://doi.org/10.1093/toxsci/kfp163 (2009).
doi: 10.1093/toxsci/kfp163
pubmed: 19638433
pmcid: 2742585
Shaw, P. J., Ganey, P. E. & Roth, R. A. Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J. Pharmacol. Exp. Ther. 328, 62–68. https://doi.org/10.1124/jpet.108.143792 (2009).
doi: 10.1124/jpet.108.143792
pubmed: 18820134
Giustarini, G. et al. Tissue influx of neutrophils and monocytes is delayed during development of trovafloxacin-induced tumor necrosis factor-dependent liver injury in mice. J. Appl. Toxicol. 38, 753–765. https://doi.org/10.1002/jat.3585 (2018).
doi: 10.1002/jat.3585
pubmed: 29377180
Giustarini, G. et al. Trovafloxacin-induced liver injury: Lack in regulation of inflammation by inhibition of nucleotide release and neutrophil movement. Toxicol Sci 167, 385–396. https://doi.org/10.1093/toxsci/kfy244 (2019).
doi: 10.1093/toxsci/kfy244
pubmed: 30247740
Poon, I. K. H. et al. Unexpected link between an antibiotic, pannexin channels and apoptosis. Nature 507, 329–334. https://doi.org/10.1038/nature13147 (2014).
doi: 10.1038/nature13147
pubmed: 24646995
pmcid: 4078991
Giustarini, G. et al. The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol. Appl. Pharmacol. 391, 114915. https://doi.org/10.1016/j.taap.2020.114915 (2020).
doi: 10.1016/j.taap.2020.114915
pubmed: 32035082
Bradham, C. A., Plümpe, J., Manns, M. P., Brenner, D. A. & Trautwein, C. I. TNF-induced liver injury. Am. J. Physiol. Gastrointest. Liver Physiol. 275, 387–392. https://doi.org/10.1152/ajpgi.1998.275.3.G387 (1998).
doi: 10.1152/ajpgi.1998.275.3.G387
Woolbright, B. L. & Jaeschke, H. Mechanisms of inflammatory liver injury and drug-induced hepatotoxicity. Curr. Pharmacol. Rep. 4, 346–357. https://doi.org/10.1007/s40495-018-0147-0 (2018).
doi: 10.1007/s40495-018-0147-0
pubmed: 30560047
pmcid: 6294466
Bonzo, J. A. et al. Differential effects of trovafloxacin on TNF-α and IL-6 profiles in a rat hepatocyte-Kupffer cell coculture system. Appl. Vitro Toxicol. 1, 45–54. https://doi.org/10.1089/aivt.2014.0004 (2015).
doi: 10.1089/aivt.2014.0004
Schmidt-Arras, D. & Rose-John, S. IL-6 pathway in the liver: From physiopathology to therapy. J. Hepatol. 64, 1403–1415. https://doi.org/10.1016/j.jhep.2016.02.004 (2016).
doi: 10.1016/j.jhep.2016.02.004
pubmed: 26867490
Masubuchi, Y. et al. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem. Biophys. Res. Commun. 304, 207–212. https://doi.org/10.1016/S0006-291X(03)00572-2 (2003).
doi: 10.1016/S0006-291X(03)00572-2
pubmed: 12705907
Kovalovich, K. et al. Increased toxin-induced liver injury and fibrosis in interleukin-6–deficient mice. Hepatology 31, 149–159. https://doi.org/10.1002/hep.510310123 (2000).
doi: 10.1002/hep.510310123
pubmed: 10613740
Feder, L. S., Todaro, J. A. & Laskin, D. L. Characterization of interleukin-1 and interleukin-6 production by hepatic endothelial cells and macrophages. J. Leukoc. Biol. 53, 126–132. https://doi.org/10.1002/jlb.53.2.126 (1993).
doi: 10.1002/jlb.53.2.126
pubmed: 8445325
Vidal-Vanaclocha, F. et al. IL-18 regulates IL-1β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc. Natl. Acad. Sci. 97, 734–739. https://doi.org/10.1073/pnas.97.2.734 (2000).
doi: 10.1073/pnas.97.2.734
pubmed: 10639148
pmcid: 15399
Wu, J. et al. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology 129, 363–374. https://doi.org/10.1111/j.1365-2567.2009.03179.x (2010).
doi: 10.1111/j.1365-2567.2009.03179.x
pubmed: 19922426
pmcid: 2826681
Wang, Y., Zhang, Y., Liu, Y., Xu, J. & Liu, Y. Gut-liver axis: Liver sinusoidal endothelial cells function as the hepatic barrier in colitis-induced liver injury. Front. Cell Dev. Biol. 9, 702890. https://doi.org/10.3389/fcell.2021.702890 (2021).
doi: 10.3389/fcell.2021.702890
pubmed: 34336855
pmcid: 8322652
Dong, W. et al. Toxic metals stimulate inflammatory cytokines in hepatocytes through oxidative stress mechanisms. Toxicol. Appl. Pharmacol. 151, 359–366. https://doi.org/10.1006/taap.1998.8481 (1998).
doi: 10.1006/taap.1998.8481
pubmed: 9707512
Thornton, A. J., Strieter, R. M., Lindley, I., Baggiolini, M. & Kunkel, S. L. Cytokine-induced gene expression of a neutrophil chemotactic factor/IL-8 in human hepatocytes. J. Immunol. 144, 2609 (1990).
doi: 10.4049/jimmunol.144.7.2609
pubmed: 2156928
González-Amaro, R. et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J. Exp. Med. 179, 841–848. https://doi.org/10.1084/jem.179.3.841 (1994).
doi: 10.1084/jem.179.3.841
pubmed: 7509363
Saad, B., Frei, K., Scholl, F. A., Fontana, A. & Maier, P. Hepatocyte-derived Interleukin-6 and tumor-necrosis factor α mediate the lipopolysaccharide-induced acute-phase response and nitric oxide release by cultured rat hepatocytes. Eur. J. Biochem. 229, 349–355. https://doi.org/10.1111/j.1432-1033.1995.0349k.x (1995).
doi: 10.1111/j.1432-1033.1995.0349k.x
pubmed: 7538077
Tanaka, Y., Yamato, M., Okano, T., Kitamori, T. & Sato, K. Evaluation of effects of shear stress on hepatocytes by a microchip-based system. Meas. Sci. Technol. 17, 3167. https://doi.org/10.1088/0957-0233/17/12/S08 (2006).
doi: 10.1088/0957-0233/17/12/S08
DeLeve, L. D., Wang, X., Hu, L., McCuskey, M. K. & McCuskey, R. S. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G757–G763. https://doi.org/10.1152/ajpgi.00017.2004 (2004).
doi: 10.1152/ajpgi.00017.2004
pubmed: 15191879
Liguori, M. J. et al. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 41, 177–186. https://doi.org/10.1002/hep.20514 (2005).
doi: 10.1002/hep.20514
pubmed: 15619227
Guillouzo, A. et al. The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168, 66–73. https://doi.org/10.1016/j.cbi.2006.12.003 (2007).
doi: 10.1016/j.cbi.2006.12.003
pubmed: 17241619
Kanebratt, K. P. & Andersson, T. B. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 36, 1444. https://doi.org/10.1124/dmd.107.020016 (2008).
doi: 10.1124/dmd.107.020016
pubmed: 18385292
Lübberstedt, M. et al. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J. Pharmacol. Toxicol. Methods 63, 59–68. https://doi.org/10.1016/j.vascn.2010.04.013 (2011).
doi: 10.1016/j.vascn.2010.04.013
pubmed: 20460162
Nelson, L. J. et al. Human hepatic HepaRG cells maintain an organotypic phenotype with high intrinsic CYP450 activity/metabolism and significantly outperform standard HepG2/C3A cells for pharmaceutical and therapeutic applications. Basic Clin. Pharmacol. Toxicol. 120, 30–37. https://doi.org/10.1111/bcpt.12631 (2017).
doi: 10.1111/bcpt.12631
pubmed: 27285124
Fraczek, J., Bolleyn, J., Vanhaecke, T., Rogiers, V. & Vinken, M. Primary hepatocyte cultures for pharmaco-toxicological studies: At the busy crossroad of various anti-dedifferentiation strategies. Arch. Toxicol. 87, 577–610. https://doi.org/10.1007/s00204-012-0983-3 (2013).
doi: 10.1007/s00204-012-0983-3
pubmed: 23242478
Elvevold, K., Smedsrød, B. & Martinez, I. The liver sinusoidal endothelial cell: A cell type of controversial and confusing identity. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G391–G400. https://doi.org/10.1152/ajpgi.00167.2007 (2008).
doi: 10.1152/ajpgi.00167.2007
pubmed: 18063708
Heuff, G., Van Loosdrecht, A. A. D., Betjes, M. G. H., Beelen, R. H. J. & Meijer, S. Isolation and purification of large quantities of fresh human Kupffer cells, which are cytotoxic against colon carcinoma. Hepatology 21, 740–745. https://doi.org/10.1002/hep.1840210322 (1995).
doi: 10.1002/hep.1840210322
pubmed: 7875672
Raasch, M., Fritsche, E., Kurtz, A., Bauer, M. & Mosig, A. S. Microphysiological systems meet hiPSC technology—New tools for disease modeling of liver infections in basic research and drug development. Adv. Drug Deliv. Rev. 140, 51–67. https://doi.org/10.1016/j.addr.2018.06.008 (2019).
doi: 10.1016/j.addr.2018.06.008
pubmed: 29908880
Gripon, P. et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. 99, 15655–15660. https://doi.org/10.1073/pnas.232137699 (2002).
doi: 10.1073/pnas.232137699
pubmed: 12432097
pmcid: 137772
Kmiec, Z. Cooperation of liver cells in health and disease. Adv. Anat. Embryol. Cell Boil. 161, III–XIII, 1, Doi: https://doi.org/10.1007/978-3-642-56553-3_7 (2001).
Lalor, P. F. & Adams, D. H. Adhesion of lymphocytes to hepatic endothelium. Mol. Pathol. 52, 214–219. https://doi.org/10.1136/mp.52.4.214 (1999).
doi: 10.1136/mp.52.4.214
pubmed: 10694942
pmcid: 395702
Rashidi, H., Alhaque, S., Szkolnicka, D., Flint, O. & Hay, D. C. Fluid shear stress modulation of hepatocyte-like cell function. Arch. Toxicol. 90, 1757–1761. https://doi.org/10.1007/s00204-016-1689-8 (2016).
doi: 10.1007/s00204-016-1689-8
pubmed: 26979076
pmcid: 4894932
Xu, J. J. et al. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105, 97–105. https://doi.org/10.1093/toxsci/kfn109 (2008).
doi: 10.1093/toxsci/kfn109
pubmed: 18524759
Fish, D. N. & Chow, A. T. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 32, 101–119. https://doi.org/10.2165/00003088-199732020-00002 (1997).
doi: 10.2165/00003088-199732020-00002
pubmed: 9068926
Vincent, J., Teng, R., Dalvie, D. K. & Friedman, H. L. Pharmacokinetics and metabolism of single oral doses of trovafloxacin. Am. J. Surg. 176, 8S-13S. https://doi.org/10.1016/S0002-9610(98)00213-X (1998).
doi: 10.1016/S0002-9610(98)00213-X
pubmed: 9935250
Teng, R. et al. Pharmacokinetics and safety of trovafloxacin (CP-99, 219), a new quinolone antibiotic, following adminstration of single oral doses to healthy male volunteers. J. Antimicrob. Chemother. 36, 385–394. https://doi.org/10.1093/jac/36.2.385 (1995).
doi: 10.1093/jac/36.2.385
pubmed: 8522468
Lubasch, A., Keller, I., Borner, K., Koeppe, P. & Lode, H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 44, 2600–2603. https://doi.org/10.1128/AAC.44.10.2600-2603.2000 (2000).
doi: 10.1128/AAC.44.10.2600-2603.2000
pubmed: 10991830
pmcid: 90121